



## **ACARIX IS ATTENDING 2023 BIO CEO & INVESTOR CONFERENCE IN NEW YORK CITY**

**Acarix, a leader in innovative acoustic and AI-based cardiac diagnostics, will be attending for the first time the 25th annual BIO CEO & Investor Conference in New York City, February 6-9, 2023.**

The BIO CEO & Investor Conference is recognized as a premier event for C-Suite executive leaders, investors and banking communities, focusing on established as well as emerging companies, publicly traded and select private companies delivering innovation in health care.

### **For more information contact:**

Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email [helen.round@acarix.com](mailto:helen.round@acarix.com)

Christian Lindholm, CFO, phone +46 705 118333, email [christian.lindholm@acarix.com](mailto:christian.lindholm@acarix.com)

### **About Acarix**

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se)) is Certified Advisor of Acarix. For more information, please visit [www.acarix.com](http://www.acarix.com).

### **Attachments**

[Acarix is attending 2023 BIO CEO & Investor Conference in New York City](#)